Vaccination COVID-19 : technologies vaccinales, efficacité en vie réelle et spécificités

The rapid development and accelerated evaluation of effective vaccines against SARS-CoV-2 have made it possible to partially control the COVID-19 pandemic, responsible for an unprecedented health crisis. In June 2022, six vaccines are authorized in Europe, eleven are recognized by the World Health Organization and more than 160 candidate vaccines are in clinical development. The remarkable efficacy of these vaccines assessed in pivotal trials has been confirmed effectiveness trials. Current efficacy data against the Omicron variant show limited protection conferred by primary vaccination against symptomatic forms, but which remains significant against severe forms. Vaccine efficacy is partially restored by administration of a booster dose. The reassuring data on immunogenicity and safety of heterologous regimens, the possible interchangeability between mRNA vaccines are all valuable tools to facilitate the intensification of vaccination campaigns and consider new vaccine strategies.